108 related articles for article (PubMed ID: 29454888)
41. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Toblli JE; Di Gennaro F
PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
[TBL] [Abstract][Full Text] [Related]
42. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
43. Review of available intravenous iron preparations in hemodialysis.
Palmer K; Cameron K; Battistella M
CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
[No Abstract] [Full Text] [Related]
44. Parenteral iron nephrotoxicity: potential mechanisms and consequences.
Zager RA; Johnson AC; Hanson SY
Kidney Int; 2004 Jul; 66(1):144-56. PubMed ID: 15200421
[TBL] [Abstract][Full Text] [Related]
45. Iron Treatment Strategies in Dialysis-Dependent CKD.
Pandey R; Daloul R; Coyne DW
Semin Nephrol; 2016 Mar; 36(2):105-11. PubMed ID: 27236131
[TBL] [Abstract][Full Text] [Related]
46. Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator.
Toblli JE; Cao G; Angerosa M
Biometals; 2015 Apr; 28(2):279-92. PubMed ID: 25609135
[TBL] [Abstract][Full Text] [Related]
47. [Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease].
Potthoff SA; Münch HG
Dtsch Med Wochenschr; 2013 Jun; 138(24):1312-7. PubMed ID: 23737117
[TBL] [Abstract][Full Text] [Related]
48. The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
Anirban G; Kohli HS; Jha V; Gupta KL; Sakhuja V
Ren Fail; 2008; 30(6):629-38. PubMed ID: 18661414
[TBL] [Abstract][Full Text] [Related]
49. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of toxicity and oxidative stress induced by intravenous iron isomaltoside 1000 in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(10):553-65. PubMed ID: 22164963
[TBL] [Abstract][Full Text] [Related]
51. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study.
Viethen T; Gerhardt F; Dumitrescu D; Knoop-Busch S; ten Freyhaus H; Rudolph TK; Baldus S; Rosenkranz S
Int J Cardiol; 2014 Aug; 175(2):233-9. PubMed ID: 24880481
[TBL] [Abstract][Full Text] [Related]
52. [Iron deficiency : a new target in treating chronic heart failure ?].
Borgeaud M; Perrier A
Rev Med Suisse; 2016 Oct; 12(535):1747-1751. PubMed ID: 28692214
[TBL] [Abstract][Full Text] [Related]
53. Effects of Total Dose Infusion of Iron Intravenously in Patients With Acute Heart Failure and Anemia (Hemoglobin < 13 g/dl).
Kaminsky BM; Pogue KT; Hanigan S; Koelling TM; Dorsch MP
Am J Cardiol; 2016 Jun; 117(12):1942-6. PubMed ID: 27161817
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and toxicity of intravenous iron in a mouse model of critical care anemia*.
Heming N; Lettéron P; Driss F; Millot S; El Benna J; Tourret J; Denamur E; Montravers P; Beaumont C; Lasocki S
Crit Care Med; 2012 Jul; 40(7):2141-8. PubMed ID: 22564959
[TBL] [Abstract][Full Text] [Related]
55. Intravenous ferric carboxymaltose accelerates erythropoietic recovery from experimental malarial anemia.
Maretty L; Sharp RE; Andersson M; Kurtzhals JA
J Infect Dis; 2012 Apr; 205(7):1173-7. PubMed ID: 22357662
[TBL] [Abstract][Full Text] [Related]
56. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia.
Breymann C; Gliga F; Bejenariu C; Strizhova N
Int J Gynaecol Obstet; 2008 Apr; 101(1):67-73. PubMed ID: 18234203
[TBL] [Abstract][Full Text] [Related]
57. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Geisser P; Rumyantsev V
Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
[TBL] [Abstract][Full Text] [Related]
58. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy.
Zager RA
Kidney Int; 2005 Oct; 68(4):1533-42. PubMed ID: 16164630
[TBL] [Abstract][Full Text] [Related]
59. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.
Sane R; Baribeault D; Rosenberg CL
Pharmacotherapy; 2007 Apr; 27(4):613-5. PubMed ID: 17381390
[TBL] [Abstract][Full Text] [Related]
60. [Oral iron administration through drinking water as compared with parenteral administration of iron dextran preparations in piglets].
Meyer P; Matzke P; Peschke W; Kaufmann G
Berl Munch Tierarztl Wochenschr; 1975 Nov; 88(21):409-12. PubMed ID: 1200962
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
